PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
 
J Exp Med. 1998 December 21; 188(12): 2375–2380.
PMCID: PMC2212426

Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells

Abstract

Mature natural killer (NK) cells use Ca2+-dependent granule exocytosis and release of cytotoxic proteins, Fas ligand (FasL), and membrane-bound or secreted cytokines (tumor necrosis factor [TNF]-α) to induce target cell death. Fas belongs to the TNF receptor family of molecules, containing a conserved intracytoplasmic “death domain” that indirectly activates the caspase enzymatic cascade and ultimately apoptotic mechanisms in numerous cell types. Two additional members of this family, DR4 and DR5, transduce apoptotic signals upon binding soluble TNF-related apoptosis-inducing ligand (TRAIL) that, like FasL, belongs to the growing TNF family of molecules. Here, we report that TRAIL produced or expressed by different populations of primary human NK cells is functional, and represents a marker of differentiation or activation of these, and possibly other, cytotoxic leukocytes. During differentiation NK cells, sequentially and differentially, use distinct members of the TNF family or granule exocytosis to mediate target cell death. Phenotypically immature CD161+/CD56 NK cells mediate TRAIL-dependent but not FasL- or granule release–dependent cytotoxicity, whereas mature CD56+ NK cells mediate the latter two.

Keywords: natural killer cells, differentiation, cytotoxicity, TRAIL, Fas ligand

Cytotoxic T lymphocytes (CTLs) and NK cells use a combination of several mechanisms to lyse different target cells. These include (a) Ca2+-dependent granule exocytosis and release of cytotoxic proteins (perforin and granzymes) from intracytoplasmic granules; (b) FasL, constitutively expressed or induced upon interaction with target cells and inducing Ca2+-independent, Fas (CD95/Apo 1)-mediated apoptosis; and (c) membrane-bound or secreted cytokines (TNF-α) (1–5; for a review, see reference 6). Fas and the TNF-R (CD120a, b) belong to a family of molecules containing a conserved intracytoplasmic “death domain” (7, 8) that, through interaction with distinct intermediary adaptor molecules, indirectly results in activation of the caspase enzymatic cascade (9) and ultimately apoptotic mechanisms in numerous cell types (7). Additional members of this family include the death receptors DR4 (R1) and DR5 (R2) (1012), transducing apoptotic signals upon binding their soluble ligand, the TNF-related apoptosis-inducing ligand (TRAIL [13]). A third receptor (R3), homologous to the other two in its extracellular domain but anchored to the membrane via glycosyl phosphatidylinositol and lacking intracellular domain and apoptosis- inducing capability (14), has been suggested to function as a decoy receptor, protecting normal cells against TRAIL- induced apoptosis.

Engagement of the TCR/CD3 complex on T cells induces increased functional expression of FasL (15). Although most CD4+ T cell–mediated cytotoxicity is Fas/ FasL dependent (16), one report indicates Fas/FasL-independent CD4+ cell–mediated lysis of certain melanoma cell lines (17), suggesting that different members in the same families may also be involved in target cell lysis by CTLs.

Upon stimulation with cytokines (18), appropriate target cells (4, 19), or FcγRIIIA ligands (20), functional FasL is induced on NK cells at significant levels and in appropriate configuration to cross-link Fas on positive target cells (e.g., Jurkat) and induce their death. TRAIL expression, and its possible role in cytotoxicity mediated by these cells, has not been analyzed. Here we demonstrate that TRAIL produced and/or expressed by different populations of human primary NK cells is functional and represents a marker of differentiation and/or activation of these and possibly other cytotoxic leukocytes.

Materials and Methods

mAbs and Polyclonal Sera.

mAbs to CD2 (B67.1, B67.6), CD4 (B66.6), CD5 (B36.1), CD8 (B116.1), CD11b (B43.4), CD14 (B52.1), CD15 (B40.9), CD56 (B159.5 [21, 22]), CD161/NKR-P1A (B199.2) used for cell purification (23), and the TNF-α– neutralizing mAb (B154.2, B154.7 [24]) have been reported previously. mAbs to CD3 (OKT3), CD21 (THB5), CD34, CD32 (IV.3), CD64 (32.2), and the irrelevant P3x63.Ag8.653 Ig were produced from cells from the American Type Culture Collection (Rockville, MD). The Fas-blocking ZB4 mAb and the Fas-triggering CH11 mAb (25) were from Upstate Biotechnology, Inc. (Lake Placid, NY). The goat anti–mouse Ig used for panning was produced in our laboratory, adsorbed on human IgG, and affinity-purified on mouse Ig Sepharose before use (26).

NK Cell Populations.

Immature lineage negative (Lin) progenitor cell populations were enriched, as described (23), from umbilical cord blood samples provided by Dr. R. Depp (Department of Obstetrics and Gynecology, Thomas Jefferson University Hospital, Philadelphia, PA). These were >99% CD3/CD161/ CD16/CD56 (indirect immunofluorescence [23]), not cytotoxic against K562 target cells, and did not express CD16 mRNA (reverse transcription [RT]-PCR) or CD161 (23; and data not shown). Their differentiation to NK cells was induced upon coculture with the murine bone marrow stromal cell line Sl/Sl4 hSCF220 (Sl/Sl4 [27]; provided by Dr. D. Williams, University of Indiana, Indianapolis, IN) and rIL-2 (50 U/ml; Hoffman-LaRoche, Nutley, NJ, through the Biological Response Modifiers Program, National Cancer Institute, Bethesda, MD) or rIL-15 (10 ng/ml, specific activity 2.95 × 108 U/mg; Immunex Corp., Seattle, WA) during a 20–30-d culture period (23, 28). CD161+/ CD56 immature and CD56+ mature NK cells were purified (23) from CD3/CD161+ cells from 25–30-d cultures with IL-2. Homogeneous populations of CD3/CD56+/CD16+ NK cells were also obtained by negative selection from short-term, 10-d cultures of umbilical cord blood lymphocytes with 30 Gy–irradiated RPMI-8866 cells (22). Each population contained >98% cells expressing the appropriate phenotype (direct immunofluorescence).

Soluble TRAIL, Fas, DR4, and DR5.

As described (10), Fas, DR4, and DR5 extracellular ligand-binding domain–Fc fusion proteins were produced in human 293 cells transiently transfected with constructs encoding these proteins. Conditioned media were used as source of the soluble proteins. Recombinant His 6–tagged TRAIL was produced in bacteria and purified by affinity chromatography on Ni2+ affinity resin.

Cytotoxicity and Cell Death.

Cell-mediated cytotoxicity was analyzed in 4- or 6-h 51Cr-release assays using, respectively, the Fas K562 and the Fas+/DR4+ Jurkat cells (J32 clone) as targets (5 × 103/well) and a series of effector cell numbers; LU were calculated at 45% specific 51Cr release (21). When indicated, 1 mM EGTA and 2 mM MgCl2, the Fas-blocking ZB4 or the irrelevant P3x63.Ag8.653 mAb as control (each 1 μg/ml), the Fas-triggering CH11 mAb (0.2 μg/ml), the TNF-α–neutralizing mAb (ascites, 1:500 dilution), His 6-tagged TRAIL (supernatant, 1:400 dilution), and DR4– and DR5–Fc fusion proteins (supernatants, 1:2 dilution) were present throughout the assay. When indicated, effector cells were preincubated (5 × 106 cell/ml, 18 h, 37°C) with rIL-2 (50 U/ml) and rIL-12 (2 ng/ml, specific activity 4.5 × 106 U/mg protein in an IFN-γ–inducing assay; provided by Dr. S. Wolf, Genetics Institute, Andover, MA). J32 cell death was analyzed in a 6-h 51Cr-release assay with the indicated reagents present throughout the assay. rTNF-α (specific activity 107 U/mg protein on L929 cells, α subline), was provided by Dr. J.S. Price, Cetus Corp., Emeryville, CA.

RT-PCR Analysis.

RT-PCR was performed as described (23) on total RNA extracted from the different cell populations (5 × 104 cells/sample) with RNAzol (Biotecx Laboratories, Houston, TX). FasL and TRAIL primers (produced at the Kimmel Cancer Center Nucleic Acid Facility) used for RT were, respectively, TGGTTGCCTTGGTAGGATTGGGC (5′) and GAGCTTATATAAGCCGAAAAACG (3′) (29), and AACCTCTGAGGAAACCAT (5′) and TTAGCCAACTAAAAAGGC (3′). β-actin primers were published previously (23). RT-PCR products were identified on agarose gels after ethidium bromide staining.

Results and Discussion

NK cells induced to differentiate from Lin umbilical cord blood cells in cultures with IL-15 mediated lower levels of cytotoxicity against K562 target cells than those mediated by cells from cultures with IL-2 (Fig. (Fig.11 a), but cells from either culture condition, such as mature adult peripheral or umbilical cord blood NK cells (26, 30), mediated similar levels of cytotoxicity after stimulation with IL-2 and IL-12. In both cases cytotoxicity was restricted to the CD3/CD161+/CD56+ NK cell population, the only one detected in cultures with IL-15 (our unpublished data; Fig. Fig.1,1, b and c). An additional immature CD161+/CD56 NK cell population generated in cultures with IL-2 neither produces IFN-γ (23) nor mediates cytotoxicity against K562 cells (Fig. (Fig.11 c) although, like mature NK cells, cells in this population contain perforin and enzymatically active granzyme B (23) and form conjugates with K562 cells (not shown). The inability of this cell population to kill K562 cells likely reflects a defect in either expression or granule exocytosis–triggering function of one or more NK cell receptors activating cytotoxicity or of other accessory molecules involved in it. Interestingly, however, cells in the same population reproducibly mediated significant levels of cytotoxicity against the Jurkat cell line (Fig. (Fig.11 c).

Figure 1
Development of granule exocytosis–dependent cytotoxicity during NK cell differentiation. (a) Lin umbilical cord blood cells were cultured with the Sl/Sl4 cell line and IL-2 (♦, [filled square]) or IL-15 ([open triangle], □) for ...

Killing of K562 cells by umbilical cord (Fig. (Fig.22 a) and adult peripheral blood NK cells (31; data not shown) is completely Ca2+ dependent, granule exocytosis mediated; that of the Fas+ Jurkat cell line (25) is only partially so (Fig. (Fig.22 b, using umbilical cord blood as effector cells; not shown with adult PBLs). In this case, activation of the Ca2+- and granule release–independent apoptotic death pathway(s) depends on engagement of Fas by FasL, expressed or induced at significant levels on the effector cells upon target cell interaction (18, 31). Thus, the effector cells function primarily to present target cells with the appropriate configuration of the ligand(s) (FasL) capable of binding and cross-linking membrane receptor(s) (Fas) that initiate the target cell apoptotic signals. The Ca2+-independent cytotoxicity mediated against Jurkat cells by NK cells from cultures with IL-15 or IL-2 (Fig. (Fig.2,2, c and d, respectively) was inhibited, as expected, in the presence of Fas-blocking mAb, and no greater inhibition was observed upon further addition of TNF-α–neutralizing mAb. Thus, analogous to the observations with freshly purified mature umbilical cord blood and adult peripheral blood NK cells (31), Ca2+-dependent granule exocytosis and Fas/FasL-dependent cytotoxic mechanisms account for most cytotoxic activity of mature NK cells from Lin cells under the culture conditions analyzed.

Figure 2
Granule exocytosis–dependent and independent cytotoxicity of umbilical cord blood NK cell subsets. Mature CD3/CD56+/CD16+ NK cells from short-term cultures were tested against K562 (a) or Jurkat target cells (b): cytotoxicity ...

Interestingly, the immature CD161+/CD56 NK cells from cultures with IL-2 (Fig. (Fig.22 e) also lysed Jurkat cells, although less efficiently than their mature CD56+ cell counterparts from the same culture. As expected based on lack of detectable granule exocytosis upon target cell recognition (23), Jurkat cell lysis by these cells, unlike that by mature NK cells, was essentially Ca2+ independent (Fig. (Fig.22 e). Immunofluorescence analysis revealed no detectable FasL, whereas RT-PCR detected constitutive FasL mRNA expression in all of the NK cell populations (not shown), in agreement with findings in mature adult human NK cells (19) and murine NK cell clones (18). However, Fas-blocking mAb did not inhibit killing of Jurkat cells by the immature cells (Fig. (Fig.22 e), suggesting that these use soluble or membrane-bound molecules distinct from FasL to mediate this effect.

CD161+/CD56 immature NK cells express TNF-α mRNA constitutively (23), and most produce TNF-α upon stimulation (our unpublished observations). Two lines of evidence exclude a significant role of TNF-α, either secreted (32) or in membrane-bound form (3), in Jurkat cell death: (a) no significant 51Cr release above background was detected from Jurkat cells after a 6-h incubation with up to 103 U/ml rTNF-α (not shown); and (b) no inhibition of immature NK cell–mediated Jurkat cell killing was detected in the presence of a TNF-α–neutralizing mAb, alone or with added Fas-blocking ZB4 mAb (Fig. (Fig.22 e). Similar results with cells from cultures with IL-2 (containing both mature and immature NK cells) confirmed that the TNF-α/TNF-R pathway does not participate significantly in NK cell–mediated Jurkat cell lysis under the experimental conditions used, and ligands other than TNF-α on the immature NK cells bind target cell receptors distinct from TNF-R and Fas but sharing their apoptosis-inducing activity.

Unlike K562 cells (13; not shown), Jurkat cells are sensitive both to Fas-mediated (25; not shown) and to soluble TRAIL-mediated cytotoxicity (13). Engagement of the TRAIL receptors DR4 and DR5 (10, 11) by soluble TRAIL results in apoptosis (33, 34). The J32 Jurkat cell clone used, like most clones of this cell line, undergoes apoptotic cell death upon binding either soluble TRAIL or Fas-triggering mAb (Fig. (Fig.3).3). TRAIL-induced 51Cr release was inhibited to background levels by a mixture of soluble TRAIL-Rs (DR4 and DR5), but not by soluble Fas or Fas-blocking mAb. Conversely, Fas-induced 51Cr release using Fas-triggering mAb was inhibited by the same Fas-blocking mAb, but not by the mixture of TRAIL-R–Fc fusion proteins. The lack of inhibition of the anti-Fas mAb–induced cell death by soluble Fas likely reflects inefficient competition of this molecule for the anti-Fas binding site on the mAb. These data establish that functional Fas and TRAIL-R1 and 2 (DR4 and/or DR5) are expressed on this Jurkat cell clone with their expected and exclusive specificity.

Figure 3
Fas and TRAIL sensitivity of Jurkat T cells. 51Cr-labeled J32 Jurkat cells were incubated for 6 h with the indicated reagents; released radioactivity was measured in the supernatants from triplicate wells. His 6–tagged TRAIL (1:400 dilution), ...

TRAIL mRNA expression was detectable (by RT-PCR) in the immature NK cells, although TRAIL protein was undetectable in DR4/DR5 binding analysis (data not shown). To determine whether engagement of functional TRAIL-R by TRAIL, possibly expressed or induced to significant levels on these cells upon target cell interaction, elicits Ca2+-independent target cell death, we analyzed the effect of DR4/DR5–Fc fusion proteins on cytotoxicity of mature and immature NK cells against Jurkat cells. Like the Ca2+-independent lysis mediated by mature NK cells from short-term (10-d) cultures of primary PBLs (Fig. (Fig.44 a), that mediated by CD161+/CD56+ mature NK cells from cultures with IL-15 (not shown) was reproducibly inhibited by the Fas-blocking mAb, but not by the DR4/DR5–Fc fusion proteins. Addition of these to the anti-Fas mAb in the presence of EGTA did not result in inhibition greater than that mediated by the mAb alone. However, at the same concentrations, these reagents significantly inhibited J32 cell lysis by immature NK cells (Fig. (Fig.44 b; >75%, as quantitated based on LU in the cell populations). This indicates that the molecules transducing apoptotic signals in this case are either or both DR4 and DR5, thus implicating TRAIL in the cytotoxicity mediated by this cell subset. No additional inhibition was observed under the same conditions with ZB4 mAb added, excluding a major role, if any, for the Fas/FasL-dependent cytotoxic pathway by immature NK cells. The possibility that FasL on the immature NK cells is induced, and used, at later times after interaction with the appropriate target cells is unlikely, given the relatively fast kinetics of FasL expression both in T and NK cells. However, formal proof awaits results of experiments using additional target cells in longer assays. The possibility that other (yet to be identified) molecule(s) with ligand binding specificity identical to TRAIL and in addition to it are involved in Jurkat cell killing by the immature NK cells is unlikely, based on a recent report showing anti-TRAIL Ab–mediated inhibition of Jurkat and melanoma cell lysis by cytotoxic human CD4+ T cell clones (35).

Figure 4
Differential use of TRAIL and FasL by immature and mature NK cells. Cytotoxicity of mature CD161+/CD56+ (a) and CD161+/ CD56 NK cells (b) purified from 30-d cultures of Lin umbilical cord blood cells with IL-2 ...

The data reported here provide the first direct evidence for the use of functional TRAIL, or a molecule with identical DR4/DR5 binding specificity, by primary human NK cells, and point to this as a marker of differentiation of these and possibly other cytotoxic cell types. Our results also indicate a switch in the surface molecules used for target cell recognition and/or lysis during NK cell differentiation. TRAIL–TRAIL-R interactions represent the first major (but possibly not exclusive) mechanism of target cell lysis used by NK cells to mediate their functions as innate effectors of defense, and this ability is acquired by NK cells at a specific, phenotypically identifiable stage of differentiation (exclusively CD161+) that precedes acquisition of the ability to mediate granule exocytosis– or FasL-dependent cytotoxicity (23; and this paper) and to produce IFN-γ (23).

Interesting and testable questions are raised by these data related to whether (a) the same molecules are used by NK cells at different stages of differentiation to kill other target cells; (b) TRAIL and FasL are also markers of differentiation of other cytotoxic cells, or of specific functional capabilities acquired by activated mature cytotoxic effector cells or lymphocyte subsets, phenotypically similar to the immature CD161+/CD56 NK cells and present in peripheral blood (23). This possibility is suggested by preliminary data (RT-PCR, not shown) indicating TRAIL mRNA expression in mature NK cells; and (c) like granule exocytosis (for a review, see reference 36), both FasL- and TRAIL-dependent cytotoxicity are negatively regulated by MHC-binding receptors inhibiting cytotoxicity. TRAIL-Rs, expressed on numerous cell types, have been shown to be functional on transformed, but not normal cell-derived cell lines (37). Definition of the expression and functionality of these receptors on primary tumor cells and hematopoietic cells at distinct stages of differentiation or activation/proliferation is essential to establish whether the use of TRAIL rather than FasL by immature NK cells, or even (a) phenotypically identical subset among mature NK cells (23), may endow these cells with (relative) specificity in the control of tumor and possibly immature hematopoietic cell growth.

Acknowledgments

We are grateful to Dr. R. Depp and the staff of the Obstetrics and Gynecology Department of Thomas Jefferson University Hospital for providing the umbilical cord blood samples, Dr. C.-C. Liu for critical discussions and suggestions, Mr. B. Abebe for technical assistance, and Ms. M. Hoffman for editing.

Supported in part by United States Public Health Service grants CA37155, CA45284 (to B. Perussia), AG14357 (to E.S. Alnemri), and T32-CA09683 (to I.M. Bennett), and by the Charlotte Greyer Foundation (E.S. Alnemri). L. Zamai was the recipient of a Dottorato di Ricerca in Scienze Morfologiche Umane (University of Bologna, Italy) from the Italian Ministry of Research and University.

Footnotes

L. Zamai's present address is Istituto di Anatomia Umana Normale, University of Urbino, I-61029 Urbino, Italy.

References

1. Montel AH, Bochan MR, Goebel WS, Bramhi Z. Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line. Cell Immunol. 1995;165:312–317. [PubMed]
2. Lee PK, Spielman J, Zhao DY, Olsen KJ, Podack ER. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol. 1996;157:1919–1925. [PubMed]
3. Perez C, Albert I, DeFay K, Zacharides N, Gooding L, Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 1990;63:251–258. [PubMed]
4. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996;157:2909–2915. [PubMed]
5. Lowin B, Peitsch MC, Tschopp J. Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol. 1995;198:1–24. [PubMed]
6. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol. 1994;12:735–773. [PubMed]
7. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449–1456. [PubMed]
8. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem. 1993;268:10932–10937. [PubMed]
9. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1–16. [PubMed]
10. MacFarlane M, Manzoor A, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 1997;41:25417–25420. [PubMed]
11. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate NF-κB. Immunity. 1997;7:821–830. [PubMed]
12. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO (Eur Mol Biol Organ) J. 1997;16:5386–5397. [PubMed]
13. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682. [PubMed]
14. Degli-Esposti MA, Smolak PJ, Walczak J, Waugh J, Huang C-P, DuBose RF, Goodwin RG, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 1997;186:1165–1170. [PMC free article] [PubMed]
15. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Gotstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med. 1995;181:781–786. [PMC free article] [PubMed]
16. Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol. 1994;152:1127–1133. [PubMed]
17. Thomas WD, Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95) Int J Cancer. 1998;75:384–390. [PubMed]
18. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y, Kaneda K. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol. 1996;157:3967–3973. [PubMed]
19. Mori S, Jewett A, Murakami-Mori K, Cavalcanti M, Bonavida B. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother. 1997;44:282–290. [PubMed]
20. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol. 1996;156:2693–2699. [PubMed]
21. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol. 1983;130:2133–2141. [PubMed]
22. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells co-cultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987;6:171–188. [PubMed]
23. Bennett IM, Zatsepina O, Zamai L, Azzoni L, Mikheeva T, Perussia B. Definition of an NKR-P1A+/ CD56/CD16functionally immature human NK cell subset that differentiates in vitro in the presence of IL-12. J Exp Med. 1996;184:1845–1856. [PMC free article] [PubMed]
24. Cuturi MC, Murphy M, Costa-Giomi MP, Weinmann R, Perussia B, Trinchieri G. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med. 1987;165:1581–1594. [PMC free article] [PubMed]
25. Alderson M, Tough TW, Braddy S, Davis-Smith T, Roux E, Schooley K, Miller RE, Lynch DH. Regulation of apoptosis and T cell activation by Fas-specific mAb. Int Immunol. 1994;6:1799–1806. [PubMed]
26. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984;160:1147–1169. [PMC free article] [PubMed]
27. Cuturi MC, Anegon I, Sherman F, Loudon R, Clark SC, Perussia B, Trinchieri G. Production of hematopoietic colony-stimulating factors by human natural killer cells. J Exp Med. 1989;169:569–583. [PMC free article] [PubMed]
28. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169–1178. [PubMed]
29. Toksoz D, Zsebo K, Smith K, Hu S, Brankow D, Suggs SV, Martin F, Williams DA. Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene factor, stem cell factor. Proc Natl Acad Sci USA. 1992;89:7350–7354. [PubMed]
30. Gaddy J, Risdon G, Broxmeyer HE. Cord blood natural killer cells are functionally and phenotypically immature but readily respond to interleukin-2 and interleukin-12. J Interferon Cytokine Res. 1995;15:527–536. [PubMed]
31. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol. 1995;166:236–246. [PubMed]
32. Chong AS, Scuderi P, Grimes WJ, Hersh EM. Tumor targets stimulate IL-2 activated killer cells to produce interferon-γ and tumor necrosis factor. J Immunol. 1989;142:2133–2139. [PubMed]
33. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol. 1996;6:750–752. [PubMed]
34. Pitti RM, Marsters SA, Ruppert S, Donhaue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687–12690. [PubMed]
35. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand- resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol. 1998;161:2195–2200. [PubMed]
36. Renard V, Cambiaggi A, Vely F, Blery M, Olcese L, Olivero S, Bouchet M, Vivier E. Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes. Immunol Rev. 1997;155:205–221. [PubMed]
37. Gura T. How TRAIL kills cancer cells, but not normal cells. Science. 1997;277:768. [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press